Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-12-21
Based on 378 first isolates · MED-B · Febrile UTI / pyelonephritis · 2024-12-22 → 2025-12-21
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
ciprofloxacin 82 % (78 %–85 %)
Not covered: Enterococcus faecalis (8 %), Escherichia coli (4 %), Staphylococcus aureus (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
88 %
93 %
n = 28
nitrofurantoin NIT
trend · Escherichia coli not for this site
85 %
82 %
n = 28
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
83 %
89 %
n = 28
ceftriaxone CRO
trend · Escherichia coli
82 %
86 %
n = 28
ciprofloxacin CIP
trend · Escherichia coli
82 %
82 %
n = 28
mecillinam MEC
trend · Escherichia coli not for this site
81 %
82 %
n = 28
78 %
82 %
n = 28
trimethoprim TMP
trend · Escherichia coli not for this site
73 %
68 %
n = 28
49 %
43 %
n = 28
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
11 %
7 %
n = 28
3 %
7 %
n = 28
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
0 %
n = 28

Most likely organisms for this profile

Escherichia coli
60 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
8 %
Proteus mirabilis
8 %
Citrobacter freundii
4 %
Pseudomonas aeruginosa
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.